Zai Lab (ZLAB) Competitors

$18.61 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$18.53 -0.08 (-0.42%)

As of 05/22/2026 07:59 PM Eastern

ZLAB vs. ABVX, KRYS, IBRX, NUVL, and PCVX

Should you buy Zai Lab stock or one of its competitors? MarketBeat compares Zai Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zai Lab include Abivax (ABVX), Krystal Biotech (KRYS), ImmunityBio (IBRX), Nuvalent (NUVL), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

How does Zai Lab compare to Abivax?

Zai Lab (NASDAQ:ZLAB) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Zai Lab has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Abivax	N/A	-146.43%	-88.69%

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.59	-$175.54M	-$1.62	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Zai Lab currently has a consensus price target of $45.83, suggesting a potential upside of 146.28%. Abivax has a consensus price target of $137.15, suggesting a potential upside of 12.43%. Given Zai Lab's higher possible upside, equities analysts plainly believe Zai Lab is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Abivax had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Abivax and 4 mentions for Zai Lab. Abivax's average media sentiment score of 0.38 beat Zai Lab's score of -0.13 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zai Lab beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.69	$204.83M	$7.48	40.03
Zai Lab	$460.16M	4.59	-$175.54M	-$1.62	N/A

Krystal Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Zai Lab's net margin of -39.29%. Krystal Biotech's return on equity of 19.25% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Zai Lab	-39.29%	-24.32%	-15.52%

Krystal Biotech presently has a consensus target price of $324.11, suggesting a potential upside of 8.24%. Zai Lab has a consensus target price of $45.83, suggesting a potential upside of 146.28%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, Krystal Biotech had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Krystal Biotech and 4 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 0.98 beat Zai Lab's score of -0.13 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Krystal Biotech beats Zai Lab on 13 of the 17 factors compared between the two stocks.

How does Zai Lab compare to ImmunityBio?

Zai Lab (NASDAQ:ZLAB) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Zai Lab currently has a consensus target price of $45.83, suggesting a potential upside of 146.28%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 96.68%. Given Zai Lab's higher possible upside, analysts clearly believe Zai Lab is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Zai Lab has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

Zai Lab has a net margin of -39.29% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
ImmunityBio	-606.15%	N/A	-59.53%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 4.9% of Zai Lab shares are held by company insiders. Comparatively, 69.5% of ImmunityBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 46 more articles in the media than Zai Lab. MarketBeat recorded 50 mentions for ImmunityBio and 4 mentions for Zai Lab. ImmunityBio's average media sentiment score of 0.16 beat Zai Lab's score of -0.13 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	6 Very Positive mention(s)	6 Positive mention(s)	35 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.59	-$175.54M	-$1.62	N/A
ImmunityBio	$113.29M	66.75	-$351.40M	-$0.85	N/A

Summary

ImmunityBio beats Zai Lab on 9 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Zai Lab has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Zai Lab	$460.16M	4.59	-$175.54M	-$1.62	N/A

Nuvalent has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Zai Lab	-39.29%	-24.32%	-15.52%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Zai Lab had 1 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.67 beat Zai Lab's score of -0.13 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvalent currently has a consensus target price of $140.29, indicating a potential upside of 37.38%. Zai Lab has a consensus target price of $45.83, indicating a potential upside of 146.28%. Given Zai Lab's higher probable upside, analysts clearly believe Zai Lab is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Zai Lab beats Nuvalent on 8 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Zai Lab	$460.16M	4.59	-$175.54M	-$1.62	N/A

Vaxcyte has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 81.82%. Zai Lab has a consensus target price of $45.83, suggesting a potential upside of 146.28%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Zai Lab	-39.29%	-24.32%	-15.52%

In the previous week, Zai Lab had 2 more articles in the media than Vaxcyte. MarketBeat recorded 4 mentions for Zai Lab and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.66 beat Zai Lab's score of -0.13 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Zai Lab beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.11B	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-11.49	18.74	20.99	25.66
Price / Sales	4.59	323.98	559.58	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	3.19	7.09	10.44	7.14
Net Income	-$175.54M	$24.45M	$3.57B	$335.98M
7 Day Performance	1.31%	6.38%	6.37%	4.11%
1 Month Performance	-18.27%	2.43%	3.51%	2.52%
1 Year Performance	-40.58%	62.98%	34.10%	35.04%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	3.8196 of 5 stars	$18.61 flat	$45.83 +146.3%	-40.6%	$2.11B	$460.16M	N/A	1,784
ABVX Abivax	2.9528 of 5 stars	$113.55 -0.9%	$137.15 +20.8%	+2,051.5%	$9.13B	N/A	N/A	61	Earnings Report Analyst Upgrade Gap Up
KRYS Krystal Biotech	3.0368 of 5 stars	$291.75 -4.7%	$324.11 +11.1%	+139.5%	$9.03B	$389.13M	39.00	210
IBRX ImmunityBio	2.8812 of 5 stars	$8.00 +0.4%	$14.20 +77.5%	+185.4%	$8.35B	$113.29M	N/A	590	Trending News Gap Up
NUVL Nuvalent	3.2944 of 5 stars	$99.90 -2.3%	$137.25 +37.4%	+39.0%	$8.08B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors